Le Lézard
Classified in: Health
Subject: MRR

Global Liquid Biopsy Market Research 2023-2024 and 2027: The Non-Invasive Game Changer, Wide Range of Potential Uses, CGES Testing, Pharmacogenomics


DUBLIN, March 29, 2024 /PRNewswire/ -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. Technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the healthcare industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1 Market Guides
1.1 Liquid Biopsy Market - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition
2.1 What is Liquid Biopsy?
2.2 The Sequencing Revolution
2.3 Market Definition
2.4 Methodology
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier
3.1.4 Chemical/Reagent Supplier
3.1.5 Pathology Supplier
3.1.6 Independent Clinical Laboratory
3.1.7 Public National/regional Laboratory
3.1.8 Hospital Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.10 Audit Body
3.1.11 Certification Body
3.2 Using Biopsies
3.2.1 Cancer
3.2.2 Precancerous conditions
3.2.3 Inflammatory conditions
3.3 Biopsy Sites
3.4 The Situation Today - Biopsy Analysis
3.5 Evidence of Cancer - Liquid Biopsy Technology
3.5.1 The Big Picture on Liquid Biopsy Technology
3.5.2 The Role of CTCs
3.5.3 Application of CTCs
3.5.4 CellSearch Detection- Ultimate Sensitivity
3.5.5 Epic Sciences Detection- Imaging Takes the Lead
3.5.6 Maintrac Detection - The Microscope
3.5.7 Other Methods
3.5.8 ctDNA Role
3.5.9 ctDNA Applications
3.5.10 Exosomes and Micro Vesicles - New Kid on the Block
3.5.11 The Multiple Play
3.6 Cancer Treatment Protocol Under Siege
3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
3.6.2 The Cancer Screening Market Opportunity
3.6.2.1 GRAIL - What Is It?
3.6.3 Cancer Management vs. Diagnosis
3.6.3.1 The Role of Risk Assessment
3.6.3.2 Managing Therapy
3.6.3.3 Monitoring Disease - What Is It?
3.6.4 Phases of Adoption - Looking into The Future
3.6.5 The Promise of Liquid Biopsy
3.7 Structure of Industry Plays a Part
3.7.1 Hospital Testing Share
3.7.2 Economies of Scale
3.7.2.1 Hospital vs. Central Lab
3.7.3 Physician Office Lab's
3.7.4 Physician's and POCT

4 Market Trends
4.1 Factors Driving Growth
4.1.1 Non-Invasive Game Changer
4.1.2 Lower Cost
4.1.3 Greater Accuracy
4.1.4 Wide Range of Potential Uses
4.1.5 Aging Population
4.2 Factors Limiting Growth
4.2.1 Lower prices
4.2.2 Lack of Standards
4.2.3 Protocol Resistance
4.2.4 Initial Adoption Cost
4.2.5 Conclusion
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Impact of NGS on pricing
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments
5.1. Recent Developments - Importance and How to Use This Section
5.1.1. Importance of These Developments
5.1.2. How to Use This Section
5.2. Sophia Genetics to Commercialize Liquid Biopsy Test
5.3. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
5.4. Liquid Biopsy Startup Haystack Oncology Raises $56M
5.5. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
5.6. PamGene Expanding Liquid Biopsy Assays
5.7. Liquid Biopsy Firm Hedera Dx Raises ?14M
5.8. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
5.9. Precision Oncology Dx Access Varies Widely in Europe
5.10. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
5.11. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
5.12. BillionToOne Launches First Liquid Biopsy Products
5.13. Dxcover Advances Multicancer Detection Platform
5.14. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
5.15. Illumina Sues Guardant Health Over Patents
5.16. Invitae to Expand Cancer Testing Portfolio
5.17. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
5.18. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.19. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
5.20. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
5.21. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
5.22. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.23. Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
5.24. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
5.25. Bio-Techne to Acquire Asuragen for up to $320M
5.26. Personalis Broadens Liquid Biopsy Offering
5.27. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
5.28. Delfi Diagnostics Plans Multi-Cancer Screening Test
5.29. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
5.30. Liquid Biopsy NGS Panels-Diverse Test Claims
5.31. CMS Colon Cancer Screening Memo Bodes Well for Assays
5.32. Natera Liquid Biopsy Test Coverage to Expand
5.33. Freenome Closes Financing to Support Early Cancer Detection Trial
5.34. C$2.6M Liquid Biopsy Initiative
5.35. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
5.36. Liquid Biopsy Shows Promise as Screen for Cancers
5.37. Inivata launches RaDaRT for the detection of residual disease and recurrence
5.38. Liquid Biopsy Assay Detects 50+ Types of Cancer
5.39. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players (Partial List)

For more information about this report visit https://www.researchandmarkets.com/r/n91uii

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 03:31
DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative
In recent years, the rapid development of artificial intelligence has introduced new possibilities across numerous scientific disciplines. As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the...

at 03:01
Lenire from Neuromod delivers tinnitus improvement 'not demonstrated for any other treatment,' according to expert consensus
'Textbook of Tinnitus' is a comprehensive textbook that describes tinnitus, how it is caused, and state-of-the art interventions such as Lenire.Top-ranked tinnitus expert authors of the Textbook of Tinnitus state that Lenire's clinical trial results...

at 03:00
Smart Blood Analytics Swiss Achieves EU-MDR Certification for VIRUS vs. BACTERIA Model
In a significant stride towards preventing antimicrobial resistance, Smart Blood Analytics Swiss proudly announces the attainment of EU-MDR (European Medical Device Regulation)1 certification for their VIRUS vs. BACTERIA Clinical Decision Support...

at 02:43
Immunovia Publishes Interim Report for January-March 2024
January-March 2024 Net sales, which for the quarter only included royalties, amounted to SEK 156 (520)Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact.Earnings per share before...

at 02:27
Global Biometric Technologies Market Share, Trends, Size, Players, Statics, Facts, Opportunity & Forecast (2024-2031) | Pheonix Research
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Locate Bio Raises £9.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion
Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical...

More news about Health...


News published on and distributed by: